A. De Becker Archives - Page 2 of 3

01 A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stromal cells after myeloablative or non-myeloablative conditioning in patients with haematological malignancies

BJH - volume 10, issue Abstract Book BHS, february 2019

A. De Becker MD, R. Schots MD, PhD, T. Kerre MD, PhD, D. Mazure MD, J. Maertens MD, PhD, E. Baudoux , C. Lechanteur , Y. Beguin MD, PhD

A Belgian consensus protocol for autologous haematopoietic stem cell transplantation in multiple sclerosis

BJH - volume 9, issue 5, september 2018

A. Van De Velde MD, PhD, B. Willekens , L. Vanopdenbosch MD, O. Deryck , D. Selleslag MD, M. D’Haeseleer , A. De Becker MD, B. Dubois MD, PhD, D. Dierickx MD, PhD, G. Perrotta , V. De Wilde MD, PhD, V. Van Pesch MD, PhD, N. Straetmans MD, PhD, D. Dive MD, Y. Beguin MD, PhD, B. Van Wijmeersch MD, PhD, K. Theunissen MD, T. Kerre MD, PhD, G. Laureys MD, PhD

SUMMARY

Multiple sclerosis is considered to be an immune mediated inflammatory disorder of the central nervous system. It mainly affects young, socioeconomic active patients. Although our armamentarium for this disease has significantly evolved in recent years some patients remain refractory to conventional therapies. In these cases, autologous haematopoietic stem cell transplantation can be considered as a therapeutic option. Decreasing morbidity, mortality and increasing patient awareness have led to rising inquiry by our patients about this treatment option. With the aim of a standardised protocol and data registration, a Belgian working party on stem cell therapy in multiple sclerosis was established. In this paper, we report the consensus protocol of this working party on autologous haematopoietic stem cell transplantation in multiple sclerosis.

(BELG J HEMATOL 2018;9(5):167–74)

Recent advances in the treatment of acute leukemia

BJH - volume 9, issue 4, august 2018

A. De Becker MD

SUMMARY

The treatment modalities in the field of acute leukemia have seen spectacular changes in recent years. The introduction of chimeric antigen receptor T-cells (CAR T-cells) and bispecific T-cell engagers (BiTEs) dramatically improved the outcome of heavily pretreated patients with B-cell acute lymphoblastic leukemia (B-ALL). For the treatment of acute myeloid leukemia (AML), immunotherapy is more difficult to design, but also in this setting progress has been made. This text will describe recent advances in the field of acute leukemia presented at the latest EHA meeting.

(BELG J HEMATOL 2018;9(4):148–51)

Highlights in Transplantation

BJH - volume 9, issue 1, february 2018

A. De Becker MD

SUMMARY

When considering a stem cell transplantation for a patient, many factors come in to play, especially in case of an allogeneic stem cell transplantation (allo SCT). The best donor and source of stem cells should be selected, the type of conditioning must be considered and the type of underlying disease and disease status at transplant also have an impact on the outcome of the transplantation. Additionally, survival post-transplant is influenced by the occurrence of graft versus host disease (GVHD), infections, or relapsed disease. Advances in different areas of allo SCT reported at the 2017 Annual Meeting of the American Society of Hematology (ASH) will be discussed in this summary.

(BELG J HEMATOL 2018;9(1):41–3)

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

BJH - volume 8, issue Abstract Book BHS, february 2017

X. Poiré MD, PhD, C. Graux MD, PhD, A. Ory , J. Jamart , F. Frédéric , H. Schoemans MD, PhD, P. Lewalle MD, PhD, A. De Becker MD, D. Deeren MD, Z. Berneman MD, PhD, T. Kerre MD, PhD, P. Zachée MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD